© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Early Atopic Dermatitis Can Be Mild, But the Threshold for Dermatology Referral Should be Low: Mona Shahriari, MD
June 24, 2025
RAD 2025: Yale dermatologist Mona Shahriari, MD, urged primary care clinicians to refer patients with AD who don't improve to prevent cumulative emotional burden.
Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D
June 23, 2025
ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.
Primary Care-Led Weight Management Intervention Prevents Weight Gain and Enhances Revenue: New Research
June 23, 2025
ADA 2025: An intervention to emphasize weight-related care in primary care settings eliminated weight gain at the population level, researchers report.
Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data
June 23, 2025
Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.
Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults With Type 2 Diabetes
June 23, 2025
ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.
FDA Approves Clesrovimab for RSV LRTD Prevention in Infants: Daily Dose
June 23, 2025
Your daily dose of the clinical news you may have missed.
5 Late-Breaking Clinical Trials in Obesity to Watch at the ADA 85th Scientific Sessions, June 20-24, 2025
June 20, 2025
Advances in obesity pharmacotherapy will be the focus of numerous late-breaking science sessions at ADA 2025; snapshots of 5 studies follow.
ADA Standards of Care for Overweight and Obesity to Debut at 2025 Scientific Sessions
June 20, 2025
The ADA unveils the association's first Standards of Care for Overweight and Obesity, with a chapter on weight stigma and bias one of the first released.
FDA Approves Dupilumab for Treatment of Bullous Pemphigoid in Adults
June 20, 2025
Dupilumab is the first targeted treatment for BP to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.
Dual GLP-1/GLP-2 Agonist Dapiglutide Achieves 11.6% Mean Weight Loss at 28 Weeks in Phase 1b Trial
June 20, 2025
The investigational dual GLP-1/GLP-2 agonist led to 11.6% weight loss over 28 weeks with no lifestyle changes, showing strong safety and tolerability in the trial.